Palobiofarma advances it´s broad clinical pipeline
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of 2018. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients...
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of 2018. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients...
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. The trial will be conducted at Ohio State...
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial...